Insulet competitors

Kevin Sayer is the Executive Chairman of the board of directors, President and Chief Executive Officer of Dexcom. He joined Dexcom as President and Chief Operating Officer in 2011. In this executive role, Kevin was responsible for research and development, manufacturing, clinical, regulatory, finance, sales and marketing functions. During his tenure with Dexcom, he has been instrumental in leading the development of new technology, including the Dexcom G5 Mobile CGM System, the Dexcom G4 PLATINUM System with Share and several other product launches in the US and Europe. Prior to joining Dexcom, Kevin served as Chief Financial Officer of Biosensors International, a medical technology company focused on the development, manufacturing and commercialization of medical devices used in interventional cardiology and critical care procedures. Kevin also served as CFO of MiniMed, Inc. from 1994 until its acquisition by Medtronic, Inc. in 2001. Kevin received his master's and bachelor’s degrees in Accounting and Information Systems from Brigham Young University.

Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome.

John F. Sheridan has served as our President and Chief Executive Officer since March 2019 and as a member of our Board of Directors since June 2019. Prior to joining our company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation (NASDAQ: VOLC), a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.

Kevin Porter is a Chief Executive Officer at Ogden Clinic and is based in Utah. He has worked as Chief Operating Officer at Ogden Clinic and Practice Administrator at Care Point Network. Kevin studied at University of Utah David Eccles School of Business between 2005 and 2007 and University of Utah between 2005 and 2007.

+ 20 year’s experience in leading midsize and large organizations with a proven track record in strategy, sales, marketing, operations and M&A. Lived and worked in EU, USA and Asia.Track record of leading public and private equity owned companies in all major areas of business leadership including CEO, COO, President, division head. Have headed large functional teams including sales, marketing, R&D and operations/supply chain all with an international/global scope.Built high performing teams and promoted organizational diversity, agility and employee well-being, through strategic alignment/deployment, team empowerment, team building, leadership training and coaching.Have led transformational turn-arounds, change management and major restructurings.Transformed US domestic company into scalable global, matrix company.Stewarded +25 M&A deals in US, Europa and APAC.Extensive investor relations experience.Specialty: Leading large organizations with a global agenda of growth and/or major transformational needs.

Jeffrey Brewer is founder and CEO of Bigfoot Biomedical. Since his son’s 2002 diagnosis of Type 1 Diabetes (T1D), Jeffrey has been a thought leader and influencer in the diabetes community, first as a philanthropist who funded and launched the Artificial Pancreas Project along with JDRF Intl., then as JDRF’s CEO where he forged partnerships with industry to drive medical device innovation in diabetes. Jeffrey spearheaded US regulatory reform and elevated JDRF’s strategic priorities to include healthcare policy, reimbursement, and technology access. Previous to his work in diabetes, Jeffrey was an active entrepreneur where he founded and led highly successful dot-com start-ups including CitySearch and Overture / GoTo.com.